Article
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
Pessimistic
-25.0
−100 Bearish
0
+100 Bullish
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Sentiment Signal
Pessimistic
-25.0
−100Neutral+100
More Like This